Brand-name market exclusivity for nebulizer therapy to treat asthma and COPD - Nature Biotechnology

  • 📰 NatureBiotech
  • ⏱ Reading Time:
  • 7 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 6%
  • Publisher: 63%

United Kingdom News News

United Kingdom United Kingdom Latest News,United Kingdom United Kingdom Headlines

Brand-name market exclusivity for nebulizer therapy to treat asthma and COPD

This work was funded by the Commonwealth Fund, as well as from a grant to W.B.F. A.S.K.’s work was also supported by Arnold Ventures. R.B.’s work is funded by an O’Brien Institute of Public Health catalyst grant for equitable pharmaceutical innovation and access to medicines. The funders had no role in the design and conduct of the study; collection, management, analysis or interpretation of the data; review or approval of the manuscript; or decision to submit the manuscript for publication.

Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 231. in UK
 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Brand name inhalers are very good at blocking competition, better even than nebulizers, study finds NBTintheNews via endpts

BrighamWomens harvardmed UCalgaryMed PORTAL_Research wbfeldman ReedBeall

United Kingdom United Kingdom Latest News, United Kingdom United Kingdom Headlines